<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="irv70121" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id><journal-id journal-id-type="publisher-id">IRV</journal-id><journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title></journal-title-group><issn pub-type="ppub">1750-2640</issn><issn pub-type="epub">1750-2659</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394759</article-id><article-id pub-id-type="pmc">PMC12092234</article-id><article-id pub-id-type="doi">10.1111/irv.70121</article-id><article-id pub-id-type="publisher-id">IRV70121</article-id><article-id pub-id-type="other">IRV-2024-538.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Systematic Review of Prolonged SARS&#x02010;CoV&#x02010;2 Shedding in Immunocompromised Persons</article-title></title-group><contrib-group><contrib id="irv70121-cr-0001" contrib-type="author"><name><surname>Christofferson</surname><given-names>Rebecca&#x000a0;C.</given-names></name><xref rid="irv70121-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="irv70121-cr-0002" contrib-type="author"><name><surname>Giovanni</surname><given-names>Jennifer&#x000a0;E.</given-names></name><xref rid="irv70121-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="irv70121-cr-0003" contrib-type="author"><name><surname>Koumans</surname><given-names>Emily&#x000a0;H.</given-names></name><xref rid="irv70121-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="irv70121-cr-0004" contrib-type="author"><name><surname>Ategbole</surname><given-names>Muyiwa</given-names></name><xref rid="irv70121-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="irv70121-cr-0005" contrib-type="author"><name><surname>Clark</surname><given-names>Samantha&#x000a0;D.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7209-3504</contrib-id><xref rid="irv70121-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="irv70121-cr-0006" contrib-type="author"><name><surname>Godfred&#x02010;Cato</surname><given-names>Shana</given-names></name><xref rid="irv70121-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="irv70121-cr-0007" contrib-type="author"><name><surname>Menon</surname><given-names>Manoj&#x000a0;P.</given-names></name><xref rid="irv70121-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="irv70121-cr-0008" contrib-type="author"><name><surname>Sastalla</surname><given-names>Inka</given-names></name><xref rid="irv70121-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="irv70121-cr-0009" contrib-type="author"><name><surname>Schweitzer</surname><given-names>Beth&#x000a0;K.</given-names></name><xref rid="irv70121-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="irv70121-cr-0010" contrib-type="author" corresp="yes"><name><surname>Uyeki</surname><given-names>Timothy&#x000a0;M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5338-8668</contrib-id><xref rid="irv70121-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>tmu0@cdc.gov</email></address></contrib></contrib-group><aff content-type="private-address" id="irv70121-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Louisiana State University School of Veterinary Medicine</institution>
<city>Baton Rouge</city>
<named-content content-type="country-part">Louisiana</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="irv70121-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Centers for Disease Control and Prevention</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="irv70121-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Fred Hutchinson Cancer Center Seattle</institution>
<city>Seattle</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="irv70121-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Office of Genomics and Advanced Technologies</named-content>
<institution>National Institute of Allergy and Infectious Diseases</institution>
<institution>National Institutes of Health</institution>
<city>Bethesda</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Timothy M. Uyeki (<email>tmu0@cdc.gov</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>19</volume><issue seq="12">5</issue><issue-id pub-id-type="doi">10.1111/irv.v19.5</issue-id><elocation-id>e70121</elocation-id><history>
<date date-type="rev-recd"><day>07</day><month>5</month><year>2025</year></date>
<date date-type="received"><day>30</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>11</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd--><copyright-statement content-type="article-copyright">Published 2025. This article is a U.S. Government work and is in the public domain in the USA. <italic toggle="yes">Influenza and Other Respiratory Viruses</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:IRV-19-e70121.pdf"/><abstract><title>ABSTRACT</title><sec id="irv70121-sec-0001"><title>Background</title><p>Although reports have documented prolonged SARS&#x02010;CoV&#x02010;2 RNA detection in immunocompromised patients, few studies have systematically analyzed data on duration of SARS&#x02010;CoV&#x02010;2 in respiratory specimens of immunocompromised patients.</p></sec><sec id="irv70121-sec-0002"><title>Methods</title><p>A systematic review was undertaken to describe SARS&#x02010;CoV&#x02010;2 RNA and infectious virus detection in immunocompromised patients from published data between January 1, 2020 and July 1, 2022. Patients were included if there was &#x02265;&#x02009;1 positive SARS&#x02010;CoV&#x02010;2 RNA result in respiratory specimens collected &#x0003e; 20&#x02009;days since symptom onset or first positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result.</p></sec><sec id="irv70121-sec-0003"><title>Results</title><p>Of the 183 patients, 175 were symptomatic with 83 (47.4%) that experienced intermittent relapsing symptoms, while pneumonia was reported in 122 (66.7%). Immunocompromising conditions represented were hematologic malignancy treatment (89, 48.6%), solid organ transplant (47, 25.7%), autoimmune disease treatment (14, 7.7%), solid tumor treatment (3, 1.6%), HIV infection (15, 8.2%), and primary immunodeficiency (15, 8.2%). Median duration from the first to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result was 56&#x02009;days in upper respiratory and 60&#x02009;days in lower respiratory tract specimens. Significant differences in median duration of SARS&#x02010;CoV&#x02010;2 RNA detection were observed between patients with and without pneumonia and for patients with hematologic malignancies compared to solid organ transplant patients. Among patients with viral culture performed, median duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 was 60.5&#x02009;days from symptom onset (maximum 238&#x02009;days) and 59&#x02009;days from first RT&#x02010;PCR positive result (maximum 268&#x02009;days).</p></sec><sec id="irv70121-sec-0004"><title>Conclusions</title><p>Immunocompromised persons can have replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 in respiratory tissues for months, including while asymptomatic. Serial SARS&#x02010;CoV&#x02010;2 testing can inform the duration of isolation for immunocompromised patients with SARS&#x02010;CoV&#x02010;2 infection.</p></sec></abstract><kwd-group kwd-group-type="author-generated" id="Ace_Pre_40"><kwd id="irv70121-kwd-0001">COVID&#x02010;19</kwd><kwd id="irv70121-kwd-0002">immunocompromised</kwd><kwd id="irv70121-kwd-0003">SARS&#x02010;CoV&#x02010;2</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="11"/><word-count count="7100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="irv70121-ntgp-0001"><fn fn-type="funding" id="irv70121-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="paperPresentation" id="irv70121-note-0002"><p>The findings and conclusions are those of the authors and do not necessarily represent the official policy of the Centers for Disease Control and Prevention or the National Institutes of Health.</p></fn><fn fn-type="equal" id="irv70121-note-0003"><p>Rebecca C. Christofferson and Jennifer E. Giovanni contributed equally to this article.</p></fn></fn-group></notes></front><body id="irv70121-body-0001"><sec id="irv70121-sec-0005"><label>1</label><title>Introduction</title><p>The duration of severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2) in the respiratory tract of infected persons is generally well understood [<xref rid="irv70121-bib-0001" ref-type="bibr">1</xref>, <xref rid="irv70121-bib-0002" ref-type="bibr">2</xref>], but few studies have systematically reviewed SARS&#x02010;CoV&#x02010;2 RNA persistence in the respiratory tracts of immunocompromised patients. Although case reports have documented SARS&#x02010;CoV&#x02010;2 RNA in immunocompromised patients for weeks to over a year [<xref rid="irv70121-bib-0003" ref-type="bibr">3</xref>, <xref rid="irv70121-bib-0004" ref-type="bibr">4</xref>, <xref rid="irv70121-bib-0005" ref-type="bibr">5</xref>], the implications of persistent detection of SARS&#x02010;CoV&#x02010;2 are not fully understood. Viral evolution and immune evasion have been described among immunocompromised patients with persistent infection [<xref rid="irv70121-bib-0005" ref-type="bibr">5</xref>, <xref rid="irv70121-bib-0006" ref-type="bibr">6</xref>, <xref rid="irv70121-bib-0007" ref-type="bibr">7</xref>, <xref rid="irv70121-bib-0008" ref-type="bibr">8</xref>, <xref rid="irv70121-bib-0009" ref-type="bibr">9</xref>]. Understanding factors that may influence persistence of SARS&#x02010;CoV&#x02010;2 and the period during which immunocompromised patients are infectious is important to guide public health measures to limit transmission and inform clinical management.</p><p>During the COVID&#x02010;19 pandemic, the Centers for Disease Control and Prevention (CDC) recommended isolation of people with COVID&#x02010;19 who are moderately or severely immunocompromised for at least 20 days, with serial SARS&#x02010;CoV&#x02010;2 testing and consultation with an infectious disease specialist to help determine the duration of isolation and precautions. Because these recommendations were made early in the COVID&#x02010;19 pandemic when there were limited data available on the duration of SARS&#x02010;CoV&#x02010;2 persistence among immunocompromised persons, we performed a systematic review of published reports on SARS&#x02010;CoV&#x02010;2 RNA persistence exceeding 20 days in the respiratory tract of immunocompromised patients to assess whether the guidance was still applicable. We describe the clinical characteristics, disease course, and outcomes associated with prolonged detection of SARS&#x02010;CoV&#x02010;2 RNA and infectious virus in the respiratory tracts of immunocompromised patients.</p></sec><sec sec-type="materials-and-methods" id="irv70121-sec-0006"><label>2</label><title>Materials and Methods</title><sec id="irv70121-sec-0007"><label>2.1</label><title>Search Strategy and Selection Criteria</title><p>An initial search was conducted to identify publications describing immunocompromised patients with persistent detection of SARS&#x02010;CoV&#x02010;2 RNA in respiratory specimens. Immunocompromised patients were defined as those with moderate or severe immunocompromising conditions or receipt of immunosuppressive medications [<xref rid="irv70121-bib-0010" ref-type="bibr">10</xref>]. A systematic literature search was performed using key words identified from an initial retrieval of 120 publications. Additionally, the reference lists of review articles were screened for potential relevant primary studies, and the reference lists of included primary studies were further searched for studies for potential inclusion. Publications were retrieved from PubMed, Embase, Global Health, Cochrane Library, CINAHL, and Scopus databases from January 1, 2020 through July 1, 2022. Additional references were identified through reference lists and Google Scholar. The search strategy is available in the Supporting Information&#x000a0;<xref rid="irv70121-supitem-0002" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="irv70121-sec-0008"><label>2.2</label><title>Inclusion Criteria</title><p>This review included immunocompromised patients with reported SARS&#x02010;CoV&#x02010;2 RNA detection by RT&#x02010;PCR from respiratory specimens (nasopharyngeal, throat, sputum, bronchoalveolar lavage, and endotracheal tube) with at least one positive result &#x0003e; 20 days since the first onset of symptoms or &#x0003e; 20 days after an initial positive result for asymptomatic patients. Studies were included if sufficient patient level information was available on immunocompromising diagnosis and SARS&#x02010;CoV&#x02010;2 reverse transcription&#x02010;polymerase chain reaction (RT&#x02010;PCR) testing results. There were no age restrictions. Studies with at least one individual who was immunocompromised were included.</p></sec><sec id="irv70121-sec-0009"><label>2.3</label><title>Exclusion Criteria</title><p>Excluded publications were those in languages other than English, reviews without primary data, reports presented solely as abstracts at scientific conferences, preprints, those that reported data in a poster or abstract, or only reported results from testing of postmortem or nonrespiratory specimens. Publications where reinfection was established with viral genomic sequencing were excluded.</p></sec><sec id="irv70121-sec-0010"><label>2.4</label><title>Screening</title><p>Eight reviewers (RCC, SDC, MA, SGC, JG, MM, BS, TU) independently scanned the abstract, title, or both, to identify eligible publications for full&#x02010;text review, and then performed full&#x02010;text review to assess inclusion and exclusion criteria.</p></sec><sec id="irv70121-sec-0011"><label>2.5</label><title>Selection and Data Extraction</title><p>For included studies, nine reviewers (MA, RCC, SDC, SGC, JG, EK, MM, BS, and TU) independently abstracted data into an Excel spreadsheet to capture demographic, clinical, and laboratory information. Patients were included based on the availability of viral RNA persistence data (qualitative) that met the &#x0003e; 20&#x02010;day SARS&#x02010;CoV&#x02010;2 RNA positive threshold. Immunocompromising conditions were classified into six categories: immunosuppressive therapy for autoimmune disease (A), hematologic malignancy (H), human immunodeficiency virus infection (HIV), primary immunodeficiency (PI), solid organ transplant recipient (T), or solid tumor malignancy (ST). Hematologic malignancy patients were subclassified into (a) bone marrow transplant (BMT) recipient, (b) chimeric antigen receptor T&#x02010;cell (CAR&#x02010;T) therapy recipient, or (c) non&#x02010;BMT/CAR&#x02010;T recipient. Two reviewers (SC and RC) independently reviewed all included patients and rechecked the abstracted data for accuracy in consultation with one reviewer (TU) for discrepancies.</p></sec><sec id="irv70121-sec-0012"><label>2.6</label><title>Risk of Bias Assessment</title><p>Risk of bias assessment was carried out using the appropriate tool from the Joanna Briggs Institute (JBI) (i.e., either for case studies, case series, or cohort studies) [<xref rid="irv70121-bib-0011" ref-type="bibr">11</xref>, <xref rid="irv70121-bib-0012" ref-type="bibr">12</xref>, <xref rid="irv70121-bib-0013" ref-type="bibr">13</xref>]. As suggested by the appraisal tools, each included publication was subjected to appraisal by two authors (see Supporting Information Methodology for details). To assess confidence in our main effect of interest (long&#x02010;term duration of SARS&#x02010;CoV&#x02010;2 RNA detection in respiratory specimens), the following system was employed. A patient was classified as having prolonged SARS&#x02010;CoV&#x02010;2 RNA detection if (a) there was viral sequencing evidence inconsistent with SARS&#x02010;CoV&#x02010;2 reinfection between the first and last respiratory specimens that tested positive by RT&#x02010;PCR for SARS&#x02010;CoV&#x02010;2; or (b) the maximum time between first and last respiratory specimens that were positive for SARS&#x02010;CoV&#x02010;2 by RT&#x02010;PCR was &#x0003c; 90 days without a negative result between positive results. A patient was classified as having probable prolonged SARS&#x02010;CoV&#x02010;2 RNA detection if the maximum time between first and last respiratory specimens that were positive for SARS&#x02010;CoV&#x02010;2 by RT&#x02010;PCR was &#x02265; 90 days without viral sequencing data available.</p></sec><sec id="irv70121-sec-0013"><label>2.7</label><title>Data and Analyses</title><p>Data were abstracted on age, sex, immunocompromise diagnosis, presence or absence of symptoms and relapsing symptoms, hospitalization status, and the results of all RT&#x02010;PCR testing per included patient and viral culture (where available). Upper respiratory tract (U) specimens were defined as nasal, nasopharyngeal (NP), oropharyngeal (OP), or saliva. Lower (L) respiratory specimens were defined as bronchoalveolar lavage (BAL), bronchial secretion (BS), endotracheal aspirate, sputum, or tracheal biopsy. There were four patients where the respiratory specimen could not be inferred because the authors stated that &#x0201c;confirmation of SARS&#x02010;CoV&#x02010;2 infection was done by qualitative real&#x02010;time RT&#x02010;PCR assay of nasopharyngeal swabs, sputum, or lower respiratory tract aspirates [<xref rid="irv70121-bib-0014" ref-type="bibr">14</xref>].&#x0201d; Patients were classified with pneumonia if radiographic evidence of pulmonary infiltrates, opacities, or consolidation was included in the publication. The duration of viral RNA persistence was defined as the reported duration in days from the time of symptom onset to the last positive RT&#x02010;PCR result or time between the first and last positive RT&#x02010;PCR test results. The duration of infectious virus was defined as the last positive viral culture from illness onset.</p><p>For descriptive analyses, qualitative (i.e., positive/negative) RT&#x02010;PCR results from patients were used to determine the maximum duration of SARS&#x02010;CoV&#x02010;2 RNA detection in the upper versus lower respiratory tracts. Ct values without date of specimen collection were excluded. Comparisons of duration of RNA results across demographics variables and immunocompromising conditions were conducted using the Kruskal&#x02013;Wallis nonparametric analysis of variance, with significance assessed at the &#x003b1; =&#x02009;0.05 level. Where appropriate, post hoc pairwise comparisons were conducted using a Bonferroni adjustment.</p><p>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analyses (PRISMA) statement [<xref rid="irv70121-bib-0015" ref-type="bibr">15</xref>], and registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023408783). All analyses and visualizations were performed using R/R Studio (versions 4.3.2 and 2023.09.1 Build 494, respectively).</p></sec></sec><sec sec-type="results" id="irv70121-sec-0014"><label>3</label><title>Results</title><p>A total of 5,370 publications from January 1, 2020, through July 1, 2022, were identified through literature review. After screening and full&#x02010;text review of 786 studies eligible for inclusion, 139 publications from 32 countries with a total of 197 patients were identified that met inclusion criteria. Following a Risk of Bias Assessment (Supporting Information&#x000a0;<xref rid="irv70121-supitem-0002" ref-type="supplementary-material">S1</xref>), an additional 14 patients from 9 publications were excluded. The final dataset included 131 publications from 31 countries with 183 patients (Figure&#x000a0;<xref rid="irv70121-fig-0001" ref-type="fig">1</xref>). Of the included studies, 103 (78.6%) were case reports, 22 (16.8%) were case series, and 6 (4.6%) were cohort studies. In 162 (88.5%) of patients, prolonged SARS&#x02010;CoV&#x02010;2 RNA detection was confirmed based on our defined criteria, while 21 (13.0%) patients were classified with probable prolonged SARS&#x02010;CoV&#x02010;2 RNA detection. Of those classified with confirmed prolonged viral RNA detection, 115 patients had SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR positive results within 90&#x02010;days (71.0%) and 47 (29.0%) had viral sequencing evidence of prolonged SARS&#x02010;CoV&#x02010;2 RNA detection (Figure&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><fig position="float" fig-type="FIGURE" id="irv70121-fig-0001"><label>FIGURE 1</label><caption><p>PRISMA flow chart of studies screened for inclusion.</p></caption><graphic xlink:href="IRV-19-e70121-g003" position="anchor" id="jats-graphic-1"/></fig><sec id="irv70121-sec-0015"><label>3.1</label><title>Demographics</title><p>Of the 183 patients included in the analysis (Table&#x000a0;<xref rid="irv70121-tbl-0001" ref-type="table">1</xref>), 172 (94.0%) had age reported. The median age was 53 years, range 2.5 months to 76 years (interquartile range [IQR] 37, 63.5 years). Information on sex was available for 169 (92.4%) patients; of those, 91 (44.3%) were male, 78 (46.2%) were female (Table&#x000a0;<xref rid="irv70121-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="irv70121-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Characteristics of immunocompromised patients with detection of SARS&#x02010;CoV&#x02010;2 RNA included in systematic review.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of patients (<italic toggle="no">N</italic>&#x02009;=&#x02009;183)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age class</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 18&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">18&#x02013;49&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">63</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">50&#x02013;64&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">63</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#x02265;</italic> 65&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">39</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">78</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">91</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Symptomatic</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">175</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Relapsing symptoms (symptomatic patients <italic toggle="yes">n</italic>&#x02009;=&#x02009;175)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">83</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">71</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">173</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 1 admission</td><td align="center" valign="top" rowspan="1" colspan="1">69</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pneumonia diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">122</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">20</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No data provided</td><td align="center" valign="top" rowspan="1" colspan="1">41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Outcome</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Survived</td><td align="center" valign="top" rowspan="1" colspan="1">145</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Deceased</td><td align="center" valign="top" rowspan="1" colspan="1">26</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Still hospitalized at time of manuscript prep</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Immunodeficiency</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Autoimmune disease treatment</td><td align="center" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hematologic malignancy treatment</td><td align="center" valign="top" rowspan="1" colspan="1">89</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bone marrow transplant</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CAR&#x02010;T therapy</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unspecified</td><td align="center" valign="top" rowspan="1" colspan="1">74</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV, by CD4+ cell count</td><td align="center" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 50</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">50&#x02013;200</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 200</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Primary immunodeficiency</td><td align="center" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Solid tumor malignancy treatment (lung)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Solid organ transplant treatment</td><td align="center" valign="top" rowspan="1" colspan="1">47</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Heart</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Kidney</td><td align="center" valign="top" rowspan="1" colspan="1">26</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Liver</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr></tbody></table></table-wrap></sec><sec id="irv70121-sec-0016"><label>3.2</label><title>Clinical Characteristics</title><p>Among the 183 included patients, 175 were symptomatic (95.6%), and 8 were asymptomatic (4.4%) (Table&#x000a0;<xref rid="irv70121-tbl-0001" ref-type="table">1</xref>). Of the symptomatic patients, 83 (47.4%) experienced intermittent relapsing symptoms.</p><p>Information on hospitalization was reported for 180 (97.8%) of patients; among the 173 (94.5%) patients who were hospitalized, 69 (39.9%) had multiple hospital admissions. Pneumonia was reported in 122 (66.7%) of patients. Among 173 (94.5%) with outcome reported, 26 (15.0%) died, 145 (83.8%) survived, and 2 (1.2%) remained hospitalized at the time of the publications citing these patients.</p></sec><sec id="irv70121-sec-0017"><label>3.3</label><title>Immunocompromising Diagnoses</title><p>Of all 183 patients, 89 (48.6%) had an underlying hematologic malignancy, and of those, 10 (11.2%) had received a bone marrow transplant, and 5 (6.2%) had received CAR&#x02010;T therapy (Table&#x000a0;<xref rid="irv70121-tbl-0001" ref-type="table">1</xref>). Forty&#x02010;seven (25.7%) patients were solid organ transplant recipients, 14 (7.7%) had received immunosuppressive treatment for an autoimmune disease, and 3 (1.6%) patients had received treatment for solid tumor malignancies. Fifteen (8.2%) patients were diagnosed with HIV, and 15 (8.2%) had a primary immunodeficiency.</p></sec><sec id="irv70121-sec-0018"><label>3.4</label><title>Detection of Viral RNA in Respiratory Specimens (<italic toggle="no">N</italic>&#x02009;=&#x02009;183 Patients)</title><p>In 159 (86.3%) patients, the same type of clinical specimen was reported for the first and last SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR positive results. The remaining patients had unmatched respiratory specimens from the first to the last RT&#x02010;PCR result (<italic toggle="yes">n</italic> =&#x02009;20) or no data were available on the final specimen type (<italic toggle="yes">n</italic> =&#x02009;4). Among patients with those 20 unmatched specimens, 5 (25.0%) matched in specimen source location (i.e., upper vs. lower respiratory tract). Thirteen (65.0%) had an initial positive result on an upper respiratory tract specimen and a last reported positive on a lower respiratory tract specimen and two (10.0%) had initial positives on lower respiratory tract specimens and last positives on upper respiratory tract specimens. In nine patients (4.9%), multiple specimens were reported at the last timepoint for a total of 192 total specimens representing the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result. Most (155, 80.7%) specimens representing prolonged detection of SARS&#x02010;CoV&#x02010;2 RNA included in the analyses were collected from the upper respiratory tract, and of these, most were NP specimens, including NP/OP or NP/throat swab combinations (120, 62.2%) or assumed to be NP (30, 15.5%). Other respiratory specimens that tested positive for SARS&#x02010;CoV&#x02010;2 included nasal swabs (<italic toggle="yes">n</italic> =&#x02009;1), throat or nose/throat (<italic toggle="yes">n</italic> =&#x02009;4), sputum (<italic toggle="yes">n</italic> =&#x02009;7), saliva (<italic toggle="yes">n</italic> =&#x02009;2), OP (<italic toggle="yes">n</italic> =&#x02009;4), pharyngeal swabs (<italic toggle="yes">n</italic> =&#x02009;2), endotracheal/tracheal/bronchial swabs or secretions (<italic toggle="yes">n</italic> =&#x02009;9), and BAL fluid (<italic toggle="yes">n</italic> =&#x02009;11) (Table&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><p>Of the 175 symptomatic patients, 168 (96.0%) had information on time from the first to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result; the median duration of detectable SARS&#x02010;CoV&#x02010;2 RNA was 55.5 days, range 20&#x02013;404 (IQR 41, 94.5). The median duration of detectable SARS&#x02010;CoV&#x02010;2 RNA in upper respiratory tract specimens (<italic toggle="yes">n</italic> =&#x02009;147) from the first positive RT&#x02010;PCR result in symptomatic patients was 56 days, range 21&#x02013;404 days (IQR 38.5, 99), and for lower respiratory tract specimens (<italic toggle="yes">n</italic> =&#x02009;27), the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection was 68 days, range 20&#x02013;335 (IQR 45, 92.5). Among symptomatic patients, the duration from the first to the last detection of SARS&#x02010;CoV&#x02010;2 RNA varied by the following immunocompromising conditions: hematologic malignancy (median duration 72 days, <italic toggle="yes">n</italic> =&#x02009;87), solid tumor malignancy (median duration 86 days, <italic toggle="yes">n</italic> =&#x02009;3), patients receiving immunosuppressive treatment for an autoimmune disease (median duration of 53 days, <italic toggle="yes">n</italic> =&#x02009;12), HIV infection (median duration of 48 days, <italic toggle="yes">n</italic> =&#x02009;12), primary immunodeficiency (median duration of 52 days, <italic toggle="yes">n</italic> =&#x02009;15), and solid organ transplant (median duration of 41 days; <italic toggle="yes">n</italic> =&#x02009;39). However, the only statistically significant difference in median duration of detectable SARS&#x02010;CoV&#x02010;2 RNA from the first to the last positive RT&#x02010;PCR result among the immunocompromising diagnoses was that patients with hematological malignancies had significantly longer median duration of SARS&#x02010;CoV&#x02010;2 RNA detection than solid organ transplant recipients (adjusted <italic toggle="yes">p =</italic> 0.001302) (Figure&#x000a0;<xref rid="irv70121-fig-0002" ref-type="fig">2A</xref> and Table&#x000a0;<xref rid="irv70121-tbl-0002" ref-type="table">2</xref>).</p><fig position="float" fig-type="FIGURE" id="irv70121-fig-0002"><label>FIGURE 2</label><caption><p>Duration of SARS&#x02010;CoV&#x02010;2 RNA in symptomatic immunocompromised patients from (A) time from the first to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result (<italic toggle="no">N</italic>&#x02009;=&#x02009;168) and (B) time from symptom onset to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result by primary immunocompromising condition (<italic toggle="no">N</italic>&#x02009;=&#x02009;102). <bold>*</bold>Indicates significant difference between groups with 95% confidence. A&#x02009;=&#x02009;autoimmune disease treatment. H&#x02009;=&#x02009;hematologic malignancy treatment. HIV&#x02009;=&#x02009;human immunodeficiency virus infection. PI&#x02009;=&#x02009;primary immunodeficiency. ST&#x02009;=&#x02009;solid tumor treatment. T&#x02009;=&#x02009;solid organ transplant.</p></caption><graphic xlink:href="IRV-19-e70121-g001" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="irv70121-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Underlying cause of immunocompromise and median days of SARS&#x02010;CoV&#x02010;2 RNA detection among symptomatic immunocompromised patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Immunocompromising condition</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">From onset of symptoms(<italic toggle="no">N</italic>&#x02009;=&#x02009;102)</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">From the first to the last RT&#x02010;PCR +(<italic toggle="no">N</italic>&#x02009;=&#x02009;168)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Median days (range)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median days (range)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of patients</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Autoimmune disease treatment</td><td align="center" valign="top" rowspan="1" colspan="1">59.5 (26, 159)</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">53 (22, 151)</td><td align="center" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hematologic malignancy treatment</td><td align="center" valign="top" rowspan="1" colspan="1">76 (24, 226)</td><td align="center" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="top" rowspan="1" colspan="1">72 (20, 404)</td><td align="center" valign="top" rowspan="1" colspan="1">87</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone marrow transplant</td><td align="center" valign="top" rowspan="1" colspan="1">74 (49, 87)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">64.5 (22, 404)</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CAR&#x02010;T therapy</td><td align="center" valign="top" rowspan="1" colspan="1">74 (NA)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">59 (23, 172)</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unspecified</td><td align="center" valign="top" rowspan="1" colspan="1">79.5 (24, 226)</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">74.5 (20, 300)</td><td align="center" valign="top" rowspan="1" colspan="1">72</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIV, by CD4+ cell count</td><td align="center" valign="top" rowspan="1" colspan="1">46 (34, 232)</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">48 (28, 274)</td><td align="center" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 50</td><td align="center" valign="top" rowspan="1" colspan="1">72.5 (55, 90)</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">85 (45, 101)</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#x02013;200</td><td align="center" valign="top" rowspan="1" colspan="1">45 (NA)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">158 (41, 274)</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 200</td><td align="center" valign="top" rowspan="1" colspan="1">45 (34, 232)</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">41 (28, 225)</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary immunodeficiency</td><td align="center" valign="top" rowspan="1" colspan="1">69 (32, 208)</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">52 (27, 207)</td><td align="center" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Solid tumor malignancy treatment</td><td align="center" valign="top" rowspan="1" colspan="1">NA (47,146)</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">86 (29, 146)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Solid organ transplant treatment</td><td align="center" valign="top" rowspan="1" colspan="1">47 (24, 185)</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">41 (21, 335)</td><td align="center" valign="top" rowspan="1" colspan="1">39</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart</td><td align="center" valign="top" rowspan="1" colspan="1">42.5 (26, 120)</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">30.5 (23, 114)</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kidney</td><td align="center" valign="top" rowspan="1" colspan="1">45 (24, 113)</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">42.5 (21, 154)</td><td align="center" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver</td><td align="center" valign="top" rowspan="1" colspan="1">92 (48, 185)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">72 (28, 335)</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="center" valign="top" rowspan="1" colspan="1">39.5 (28, 57)</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">28 (24, 57)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr></tbody></table></table-wrap><p>For 102 symptomatic patients with date of symptom onset, the median duration from onset to the last detection of SARS&#x02010;CoV&#x02010;2 RNA was 59 days, range 24&#x02013;232 (IQR 45, 88). This included two patients with solid tumor malignancy (duration 47 and 146 days), 40 patients with hematologic malignancies (median duration 76 days), 8 patients receiving immunosuppressive treatment for an autoimmune disease (median duration 59.5 days), 12 patients with primary immunodeficiency (median duration 69 days), 8 patients with HIV infection (median duration 46 days), and 32 patients with solid organ transplant (median duration 47 days). However, the only statistically significant differences were observed in patients with hematological malignancies who had significantly longer median duration of SARS&#x02010;CoV&#x02010;2 RNA detection than solid organ transplant patients (adjusted <italic toggle="yes">p =</italic> 0.0011344) (Figure&#x000a0;<xref rid="irv70121-fig-0002" ref-type="fig">2B</xref> and Table&#x000a0;<xref rid="irv70121-tbl-0002" ref-type="table">2</xref>).</p><p>There was a significant difference in the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection from the first to the last positive RT&#x02010;PCR result between symptomatic patients with pneumonia (64.5 days, <italic toggle="yes">n</italic> =&#x02009;122) and those without pneumonia (35.5 days, <italic toggle="yes">n</italic> =&#x02009;12) (<italic toggle="yes">p =</italic> 0.01094) (Figure&#x000a0;<xref rid="irv70121-fig-0003" ref-type="fig">3A</xref>). Similarly, there was a significant difference in the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection from symptom onset to the last positive RT&#x02010;PCR result between symptomatic patients with pneumonia (68 days, <italic toggle="yes">n</italic> =&#x02009;67) and without pneumonia (36 days, <italic toggle="yes">n</italic> =&#x02009;7) (<italic toggle="yes">p =</italic> 0.004572, Figure&#x000a0;<xref rid="irv70121-fig-0003" ref-type="fig">3B</xref>).</p><fig position="float" fig-type="FIGURE" id="irv70121-fig-0003"><label>FIGURE 3</label><caption><p>Duration of SARS&#x02010;CoV&#x02010;2 RNA in symptomatic immunocompromised patients with or without pneumonia diagnosis (<italic toggle="no">N</italic>&#x02009;=&#x02009;142; 122 with pneumonia; 20 without pneumonia). (A) Time from the first to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result (<italic toggle="no">N</italic>&#x02009;=&#x02009;134, 122 with pneumonia and 12 without pneumonia) and (B) time from symptom onset to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR Result (<italic toggle="no">N</italic>&#x02009;=&#x02009;74; 67 with pneumonia; 7 without pneumonia).</p></caption><graphic xlink:href="IRV-19-e70121-g002" position="anchor" id="jats-graphic-5"/></fig><p>There was no statistically significant difference in the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection from the first to the last positive RT&#x02010;PCR result between symptomatic patients who survived (57 days, <italic toggle="yes">n</italic> =&#x02009;130) or died (61.5 days, <italic toggle="yes">n</italic> =&#x02009;26) (<italic toggle="yes">p =</italic> 0.8157) or in the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection from illness onset to the last positive RT&#x02010;PCR result among symptomatic patients who survived (59 days, <italic toggle="yes">n</italic> =&#x02009;82) or died (71 days, <italic toggle="yes">n</italic> =&#x02009;14) (<italic toggle="yes">p =</italic> 0.3176). Among symptomatic patients, no significant differences in the median duration from the first to the last positive RT&#x02010;PCR result or from illness onset to the last positive RT&#x02010;PCR result were observed in nonhospitalized versus hospitalized patients, among age groups, or by sex (Table&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><p>Among eight asymptomatic patients, the median duration from the first to the last detection of SARS&#x02010;CoV&#x02010;2 RNA was 65.5 days (range 26&#x02010;142 days). The median duration from the first to the last detection of SARS&#x02010;CoV&#x02010;2 RNA was 47 days (range 26&#x02010;111) for six asymptomatic patients who were hospitalized for reasons other than COVID&#x02010;19 at the time of the first positive SARS&#x02010;CoV&#x02010;2 test and for two patients who were never hospitalized (durations of 105 and 142 days). There were no significant differences in duration of SARS&#x02010;CoV&#x02010;2 RNA detection by age group, sex, or hospitalization status (Table&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><p>There was no significant difference in median duration of SARS&#x02010;CoV&#x02010;2 RNA detection from the first to the last positive RT&#x02010;PCR result between symptomatic (55.5 days, range 20&#x02013;404, <italic toggle="yes">n</italic> =&#x02009;168) and asymptomatic patients (65.5 days, range 26&#x02013;142, <italic toggle="yes">n</italic> =&#x02009;8) (<italic toggle="yes">p =</italic> 0.9405). Among all symptomatic and asymptomatic patients, there was no statistically significant difference in the median duration from the first to the last positive SARS&#x02010;CoV&#x02010;2 RNA results between hospitalized (55.5 days, <italic toggle="yes">n</italic> =&#x02009;166) and nonhospitalized patients (124 days, <italic toggle="yes">n</italic> =&#x02009;6) (<italic toggle="yes">p =</italic> 0.05179).</p><p>We performed a subset analysis on patients with viral genomic data and time between first and last SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR positive result (<italic toggle="yes">n</italic> =&#x02009;47). The median duration of prolonged SARS&#x02010;CoV&#x02010;2 RNA detection was 109 days (IQR [70, 197]) with a maximum reported detection of 404 days [<xref rid="irv70121-bib-0016" ref-type="bibr">16</xref>]. For 23 patients with data on time since symptom onset, the median duration of prolonged SARS&#x02010;CoV&#x02010;2 detection was 100 days (IQR [68.5, 154]) with a maximum of 232 days [<xref rid="irv70121-bib-0017" ref-type="bibr">17</xref>]. There was no significant difference in the time between the first and last RT&#x02010;PCR positive result among patients with primary immunodeficiency (Figure&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S2</xref>, <italic toggle="yes">p</italic>&#x02010;value = 0.8226) nor for time since symptom onset (<italic toggle="yes">p =</italic> 0.9856).</p></sec><sec id="irv70121-sec-0019"><label>3.5</label><title>Viral Culture</title><p>Among included patients, 50 (27.3%) patients from 39 publications had viral culture performed on respiratory specimens. Of these, 43 (86.0%) patients had one or more positive viral culture result (1 asymptomatic and 42 symptomatic patients). We focused on those respiratory specimens that represented the last timepoint from which virus was isolated. For 42 of these patients, only one specimen type was cultured at the final timepoint, whereas one patient had two specimen types that yielded recoverable virus at the final timepoint [<xref rid="irv70121-bib-0018" ref-type="bibr">18</xref>]. Virus was isolated mostly from upper respiratory specimens (39, 88.4%), including NP (<italic toggle="yes">n</italic> =&#x02009;27) or NP assumed (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5), OP (<italic toggle="yes">n</italic> =&#x02009;2), pharyngeal or throat swabs (<italic toggle="yes">n</italic> =&#x02009;3), and NP/sputum (<italic toggle="yes">n</italic> =&#x02009;1). Of the 43 patients with a positive viral culture for SARS&#x02010;CoV&#x02010;2, 27 had a hematologic malignancy, 9 were solid organ transplant recipients, 3 were receiving immunosuppressive treatment for an autoimmune disease, 2 had a primary immunodeficiency, and 1 had HIV infection.</p><p>All 43 patients with a positive viral culture had time reported since the first positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result while 21 (48.8%) patients had reported time since symptom onset. The median duration from first detection of SARS&#x02010;CoV&#x02010;2 RNA to the last positive viral culture was 59&#x02009;days, range 0&#x02013;268 (IQR 24, 101). For 21 symptomatic patients with data on date of illness onset, the median time from symptom onset to the last positive viral culture was 60.5&#x02009;days, range 0&#x02013;238 (IQR 26, 100) (Figure&#x000a0;<xref rid="irv70121-supitem-0001" ref-type="supplementary-material">S3</xref>). One asymptomatic patient (HIV patient with CD4 count &#x0003c; 50 cells/mm<sup>3</sup>) had SARS&#x02010;CoV&#x02010;2 isolated from a respiratory specimen collected 94&#x02009;days after an initial SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR positive result.</p></sec></sec><sec sec-type="discussion" id="irv70121-sec-0020"><label>4</label><title>Discussion</title><p>In this systematic review of published reports of SARS&#x02010;CoV&#x02010;2 RNA detection in respiratory specimens &#x0003e; 20 days in immunocompromised patients, the median duration from the first to the last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result was 57 days in upper respiratory and 65 days in lower respiratory tract specimens. The maximum duration of SARS&#x02010;CoV&#x02010;2 RNA detection in respiratory specimens was more than 400 days from the first positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result with viral genomic data indicating prolonged SARS&#x02010;CoV&#x02010;2 RNA detection [<xref rid="irv70121-bib-0016" ref-type="bibr">16</xref>]. Among symptomatic patients with viral culture performed, the median duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 detection from symptom onset was 60.5 days and the longest duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 was 238 days since symptom onset. In symptomatic patients without date of onset reported, the longest duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 was 268 days from the first positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result in an individual with untreated HIV. Our review suggests that immunocompromised patients hospitalized with pneumonia have prolonged SARS&#x02010;CoV&#x02010;2 infection compared to those without pneumonia. However, immunocompromised patients with severe pneumonia might be retested serially to inform isolation precautions and hospital discharge, whereas some patients with very mild symptoms or asymptomatic might not be tested for SARS&#x02010;CoV&#x02010;2 serially outside of participating in a study.</p><p>Our findings are similar to the results of recent studies of SARS&#x02010;CoV&#x02010;2 shedding in immunocompromised patients since emergence of the Omicron variant and subvariants. One prospective study published after our literature cutoff date reported that immunocompromised patients had detectable SARS&#x02010;CoV&#x02010;2 RNA for a median of 12 weeks, IQR 6&#x02010;31 weeks, with viable SARS&#x02010;CoV&#x02010;2 for a median of 4 weeks, IQR 3&#x02010;7 weeks [<xref rid="irv70121-bib-0019" ref-type="bibr">19</xref>]. Another recent prospective study reported that from the time of enrollment, 38 of 150 immunocompromised patients had evidence of SARS&#x02010;CoV&#x02010;2 RNA in respiratory specimens for more than 21 days, including 5 patients with SARS&#x02010;CoV&#x02010;2 RNA detected for 75&#x02013;207 days and viable virus detected for 30&#x02013;198 days [<xref rid="irv70121-bib-0020" ref-type="bibr">20</xref>].</p><p>Our review suggests that patients with hematologic malignancies can have longer duration of SARS&#x02010;CoV&#x02010;2 RNA and replication&#x02010;competent virus detection than other immunocompromised patients. Since our literature search cutoff date, additional studies in immunocompromised patients, including prospective studies, have reported data on prolonged SARS&#x02010;CoV&#x02010;2 RNA detection and or viral culture results. One recent prospective study reported that hematologic malignancy and transplant patients had significantly longer time to clearance of SARS&#x02010;CoV&#x02010;2 RNA and infectious virus from the upper respiratory tract compared to patients with autoimmunity or B&#x02010;cell deficiency [<xref rid="irv70121-bib-0009" ref-type="bibr">9</xref>]. Other studies have reported that hematologic malignancy requiring B&#x02010;cell depleting therapy is associated with prolonged SARS&#x02010;CoV&#x02010;2 shedding [<xref rid="irv70121-bib-0019" ref-type="bibr">19</xref>, <xref rid="irv70121-bib-0021" ref-type="bibr">21</xref>]. A recent prospective study in immunocompromised patients with hematological malignancies receiving active chemotherapy or solid organ transplant recipients reported that duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 was significantly shorter in patients with higher neutralizing antibody levels against SARS&#x02010;CoV&#x02010;2 [<xref rid="irv70121-bib-0022" ref-type="bibr">22</xref>].</p><p>A key epidemiologic parameter for SARS&#x02010;CoV&#x02010;2 transmission and determining duration of transmission&#x02010;based precautions is the presence of symptoms. However, nearly half of the symptomatic patients included in our review had relapsing symptoms of COVID&#x02010;19 and detectable SARS&#x02010;CoV&#x02010;2 RNA in respiratory specimens during asymptomatic periods, and the median duration of SARS&#x02010;CoV&#x02010;2 RNA detection was similar in symptomatic and asymptomatic patients. In our review, two asymptomatic patients had recovery of infectious SARS&#x02010;CoV&#x02010;2 for at least 70 days, and longer detection of infectious SARS&#x02010;CoV&#x02010;2 in asymptomatic immunocompromised patients has been reported [<xref rid="irv70121-bib-0023" ref-type="bibr">23</xref>]. These findings highlight that the absence of symptoms may be a potentially unreliable indicator of infectiousness among immunocompromised patients with SARS&#x02010;CoV&#x02010;2 infection. In addition, there are reports of immunocompromised patients with COVID&#x02010;19 who have improved clinically with negative results of SARS&#x02010;CoV&#x02010;2 testing of upper respiratory tract specimens, who then had relapse of symptoms with clinical deterioration weeks to months later [<xref rid="irv70121-bib-0024" ref-type="bibr">24</xref>, <xref rid="irv70121-bib-0025" ref-type="bibr">25</xref>], indicating that resolution of symptoms or even lack of detection of SARS&#x02010;CoV&#x02010;2 RNA in the upper respiratory tract of immunocompromised patients who were previously diagnosed with COVID&#x02010;19 does not exclude persistent SARS&#x02010;CoV&#x02010;2 infection.</p><p>Since prolonged detection of SARS&#x02010;CoV&#x02010;2 RNA does not necessarily inform whether infectious virus is present in the respiratory tract, and can overestimate the duration of infectious virus, viral culture results can help inform infection prevention and control measures and clinical management of immunocompromised patients with prolonged detection of SARS&#x02010;CoV&#x02010;2. The use of quantitative RT&#x02010;PCR assay results to inform whether infectious SARS&#x02010;CoV&#x02010;2 is present has been assessed by studies that correlated cycle threshold values with viral culture results for respiratory specimens. While detection of infectious SARS&#x02010;CoV&#x02010;2 has been correlated with low Ct values such as &#x0003c; 25 in some studies [<xref rid="irv70121-bib-0026" ref-type="bibr">26</xref>, <xref rid="irv70121-bib-0027" ref-type="bibr">27</xref>], other studies have reported that SARS&#x02010;CoV&#x02010;2 could be isolated from respiratory specimens from a small number of patients with Ct values &#x0003c; 37 [<xref rid="irv70121-bib-0028" ref-type="bibr">28</xref>, <xref rid="irv70121-bib-0029" ref-type="bibr">29</xref>, <xref rid="irv70121-bib-0030" ref-type="bibr">30</xref>]. However, viral culture is not available for most patients due to requirements for specialized biosafety laboratory conditions not present at clinical laboratories. Sequencing of viral RNA in respiratory specimens was used to describe viral evolution and suggest prolonged SARS&#x02010;CoV&#x02010;2 replication for 335 days in a symptomatic immunocompromised patient [<xref rid="irv70121-bib-0031" ref-type="bibr">31</xref>]. Detection of subgenomic SARS&#x02010;CoV&#x02010;2 RNA has been used by some investigators as a surrogate marker to suggest the presence of replicating virus [<xref rid="irv70121-bib-0032" ref-type="bibr">32</xref>, <xref rid="irv70121-bib-0033" ref-type="bibr">33</xref>], but most clinicians and patients do not have access to such laboratory methods outside of a research study. One study of SARS&#x02010;CoV&#x02010;2 infection in moderate to severely immunocompromised patients who received solid organ transplantation or chemotherapy against hematologic malignancy reported that SARS&#x02010;CoV&#x02010;2 rapid antigen testing had a negative predictive value of 92% for viable virus shedding in patients with symptom onset &#x0003e; 20 days [<xref rid="irv70121-bib-0019" ref-type="bibr">19</xref>].</p><sec id="irv70121-sec-0021"><label>4.1</label><title>Limitations</title><p>The findings of this review are subject to several limitations. First, due to resource limitations, our literature search was conducted as of July 1, 2022 and therefore did not include all published studies on detection of prolonged SARS&#x02010;CoV&#x02010;2 RNA or infectious virus shedding in immunocompromised patients after this date. However, as noted above, studies published after our literature search cutoff did not report longer detection of SARS&#x02010;CoV&#x02010;2 RNA or infectious virus. Second, because of publication bias, included patients did not represent all geographic regions or immunocompromised patient populations, limiting generalizability. Third, patients included in the analyses were identified from case reports and small retrospective case series without standardization of the collection of respiratory specimens, timing and intervals of sampling, specific SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR assays used, clinical and virologic data, antiviral treatments or monoclonal antibody products, or receipt of COVID&#x02010;19 vaccines, increasing variability. Fourth, the immunocompromised patients included in this review spanned a range of different SARS&#x02010;CoV&#x02010;2 variant periods, from the ancestral strain before COVID&#x02010;19 vaccines were available, and Alpha, Delta, and Omicron predominant periods, and our analyses were not able to assess differences in viral RNA or infectious virus detection due to limited virologic and genomic data. Fifth, although we excluded publications in which the authors reported that possible SARS&#x02010;CoV&#x02010;2 reinfection was present, most of the included patients did not have viral sequencing performed to assess whether reinfection with different SARS&#x02010;CoV&#x02010;2 variants had occurred. Therefore, it is possible that we might have misclassified some patients with reinfection as having prolonged duration of SARS&#x02010;CoV&#x02010;2 RNA. However, our analysis of a subset of 47 patients with available viral genomic data indicated that SARS&#x02010;CoV&#x02010;2 RNA was detectable for prolonged duration; these patients represented the maximum duration of SARS&#x02010;CoV&#x02010;2 RNA detection from the first to the last positive RT&#x02010;PCR result and from symptom onset to the last positive RT&#x02010;PCR result for all 183 included patients, increasing confidence with including all 183 patients in our analyses. Sixth, we were not able to assess and compare the effects of COVID&#x02010;19 vaccination, or antiviral or monoclonal antibody therapies on detection of viral RNA or infectious virus, as the availability of data on these and other therapies was lacking or incomplete for many patients, and some included patients were reported during the first pandemic wave before antiviral therapies were available. Seventh, the level of individual patient's degree of immunocompromise with respect to the timing of immunosuppressive medication regimens was not available. Regarding infectious virus detection, our inclusion criteria were not focused on viral culture data, and the subset of included patients with prolonged detection of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 may not be representative of all immunocompromised patients with viral culture data.</p></sec><sec id="irv70121-sec-0022"><label>4.2</label><title>Public Health Implications</title><p>These observations have public health implications for COVID&#x02010;19 prevention and mitigation efforts, particularly in the identification of immunocompromised patient groups who may be at highest risk for persistent SARS&#x02010;CoV&#x02010;2 infection and potential transmission to close contacts. Immunocompromised patients, their close contacts, and caregivers should be informed about the risk of persistent SARS&#x02010;CoV&#x02010;2 infection and the importance of isolation. Our findings indicate that serial SARS&#x02010;CoV&#x02010;2 testing of respiratory tract specimens is important to inform infection prevention and control measures and duration of isolation for moderately or severely immunocompromised persons with SARS&#x02010;CoV&#x02010;2 infection, on a case&#x02010;by&#x02010;case basis. This is consistent with CDC guidance for a test&#x02010;based strategy to be used and (if available) consultation with an infectious disease specialist to determine when transmission&#x02010;based precautions can be discontinued for patients with SARS&#x02010;CoV&#x02010;2 infection who are moderately to severely immunocompromised [<xref rid="irv70121-bib-0034" ref-type="bibr">34</xref>]. In addition to resolution of fever without use of antipyretics and improvement of symptoms, both symptomatic and asymptomatic patients should continue to isolate until results are negative from at least two consecutive respiratory specimens collected 48 h apart (total of two negative specimens) tested using an antigen test or nucleic acid amplification test [<xref rid="irv70121-bib-0034" ref-type="bibr">34</xref>].</p></sec><sec sec-type="conclusions" id="irv70121-sec-0023"><label>4.3</label><title>Conclusions</title><p>Immunocompromised persons can be potentially infectious with replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 infection for prolonged periods due to long&#x02010;term persistent infection including while asymptomatic. Persons with hematologic malignancies or solid organ transplant recipients may be more likely to have prolonged detection of SARS&#x02010;CoV&#x02010;2 RNA and infectious virus. In addition to COVID&#x02010;19 vaccination and pre&#x02010;exposure prophylaxis with monoclonal antibody products if available, further prospective research studies and clinical trials are needed to identify optimal therapies and combinations of therapies to decrease the duration of SARS&#x02010;CoV&#x02010;2 shedding in immunocompromised patients.</p></sec></sec><sec id="irv70121-sec-0031"><title>Author Contributions</title><p>
<bold>Rebecca C. Christofferson:</bold> methodology, software, data curation, formal analysis, visualization, writing &#x02013; review and editing, validation, investigation. <bold>Jennifer E. Giovanni:</bold> conceptualization, methodology, formal analysis, data curation, writing &#x02013; original draft, investigation, writing &#x02013; review and editing. <bold>Emily H. Koumans:</bold> investigation, writing &#x02013; review and editing, data curation. <bold>Muyiwa Ategbole:</bold> investigation, data curation, writing &#x02013; review and editing. <bold>Samantha D. Clark:</bold> investigation, data curation, validation, writing &#x02013; review and editing. <bold>Shana Godfred&#x02010; Cato:</bold> data curation, investigation, writing &#x02013; review and editing. <bold>Manoj P. Menon:</bold> data curation, investigation, writing &#x02013; review and editing. <bold>Inka Sastalla:</bold> data curation, investigation, writing &#x02013; review and editing. <bold>Beth K. Schweitzer:</bold> data curation, investigation, writing &#x02013; review and editing. <bold>Timothy M. Uyeki:</bold> conceptualization, methodology, investigation, validation, supervision, project administration, writing &#x02013; review and editing.</p></sec><sec id="irv70121-sec-0028"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="conclusions" id="irv70121-sec-0029"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="irv70121-sec-0027"><title>Conflicts of Interest</title><p>Shana Godfred&#x02010;Cato reports funding from HRSA for the Pediatric Pandemic Network to the University of Utah during completion of this study. All other authors declare no conflict of interest.</p></sec><sec id="irv70121-sec-0025"><sec disp-level="2" id="irv70121-sec-0032"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/irv.70121" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer&#x02010;review/10.1111/irv.70121</ext-link>.</p></sec></sec><sec id="irv70121-sec-0030"><title>Permission to Reproduce Material From Other Sources</title><p>Not applicable.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="irv70121-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Figure S1</bold> Classification of patients based on the confidence in confirming prolonged versus probable prolonged SARS&#x02010;CoV&#x02010;2 viral RNA detection and rationale.</p><p>
<bold>Figure S2:</bold> Top) Distribution of time between first and last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR results, or since symptom onset, among patients with viral genomic evidence of prolonged SARS&#x02010;CoV&#x02010;2 RNA duration (<italic toggle="no">n</italic>&#x02009;=&#x02009;47). Bottom) Distribution of duration of SARS&#x02010;CoV&#x02010;2 RNA detection according to primary immunodeficiency.</p><p>
<bold>Figure S3:</bold> Duration of replication&#x02010;competent SARS&#x02010;CoV&#x02010;2 in viral culture for symptomatic patients by time since symptom onset (top panel A, <italic toggle="no">n</italic>&#x02009;=&#x02009;21) and by time from first positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result (bottom panel B, <italic toggle="no">n</italic>&#x02009;=&#x02009;43) according to immunocompromising condition (<italic toggle="no">y</italic>&#x02010;axis). Color of the dots represents detailed immunocompromising condition.</p><p>
<bold>Table&#x000a0;S1:</bold> Summary of the type of respiratory specimens represented at the time of last positive SARS&#x02010;CoV&#x02010;2 RT&#x02010;PCR result (<italic toggle="no">n</italic>&#x02009;=&#x02009;192). *Publication lists possible specimen types as: NP, sputum, or lower respiratory tract aspirates.</p><p>
<bold>Table&#x000a0;S2:</bold> Comparison of duration of SARS&#x02010;CoV&#x02010;2 RNA detection in symptomatic patients by demographic characteristics. Comparisons were tested using Kruskal&#x02013;Wallis nonparametric test. Patients with &#x0201c;unknown&#x0201d; status for each characteristic were removed from analyses.</p><p>
<bold>Table&#x000a0;S3:</bold> Comparison of duration of SARS&#x02010;CoV&#x02010;2 RNA detection in asymptomatic patients from time from the first to the last positive SARS&#x02010;CoV&#x02010;2 result by demographic characteristics. Comparisons were tested using Kruskal&#x02013;Wallis nonparametric test. Patients with &#x0201c;unknown&#x0201d; status for each characteristic were removed from analyses.</p></caption><media xlink:href="IRV-19-e70121-s002.docx"/></supplementary-material><supplementary-material id="irv70121-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Data S1</bold> Supplementary Information.</p></caption><media xlink:href="IRV-19-e70121-s001.xlsx"/></supplementary-material></sec></body><back><ack id="irv70121-sec-0024"><title>Acknowledgments</title><p>The authors thank Sapna Bamrah Morris and Joanna Taliano, Centers for Disease Control and Prevention (CDC) for their support of the project.</p></ack><sec sec-type="data-availability" id="irv70121-sec-0026"><title>Data Availability Statement</title><p>Data are provided as Supporting Information.</p></sec><ref-list content-type="cited-references" id="irv70121-bibl-0001"><title>References</title><ref id="irv70121-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="irv70121-cit-0001">
<string-name>
<given-names>M.</given-names>
<surname>Cevik</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tate</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Lloyd</surname>
</string-name>, <string-name>
<given-names>A. E.</given-names>
<surname>Maraolo</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Schafers</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Ho</surname>
</string-name>, &#x0201c;<article-title>SARS&#x02010;CoV&#x02010;2, SARS&#x02010;CoV, and MERS&#x02010;CoV Viral Load Dynamics, Duration of Viral Shedding, and Infectiousness: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Lancet Microbe</source>
<volume>2</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>e13</fpage>&#x02013;<lpage>e22</lpage>, <pub-id pub-id-type="doi">10.1016/s2666-5247(20)30172-5</pub-id>.<pub-id pub-id-type="pmid">33521734</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="irv70121-cit-0002">
<string-name>
<given-names>Y.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Guo</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yuan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Duration of Viable Virus Shedding and Polymerase Chain Reaction Positivity of the SARS&#x02010;CoV&#x02010;2 Omicron Variant in the Upper Respiratory Tract: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>International Journal of Infectious Diseases</source>
<volume>129</volume> (<year>2023</year>): <fpage>228</fpage>&#x02013;<lpage>235</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijid.2023.02.011</pub-id>.<pub-id pub-id-type="pmid">36804640</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="irv70121-cit-0003">
<string-name>
<given-names>V. A.</given-names>
<surname>Avanzato</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Matson</surname>
</string-name>, <string-name>
<given-names>S. N.</given-names>
<surname>Seifert</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Case Study: Prolonged Infectious SARS&#x02010;CoV&#x02010;2 Shedding From an Asymptomatic Immunocompromised Individual With Cancer</article-title>,&#x0201d; <source>Cell</source>
<volume>183</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>1901</fpage>&#x02013;<lpage>1912e9</lpage>, <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.049</pub-id>.<pub-id pub-id-type="pmid">33248470</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="irv70121-cit-0004">
<string-name>
<given-names>A. N.</given-names>
<surname>Alshukairi</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>El&#x02010;Kafrawy</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Dada</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Re&#x02010;Infection With a Different SARS&#x02010;CoV&#x02010;2 Clade and Prolonged Viral Shedding in a Hematopoietic Stem Cell Transplantation Patient</article-title>,&#x0201d; <source>International Journal of Infectious Diseases</source>
<volume>110</volume> (<year>2021</year>): <fpage>267</fpage>&#x02013;<lpage>271</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijid.2021.07.036</pub-id>.<pub-id pub-id-type="pmid">34289407</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="irv70121-cit-0005">
<string-name>
<given-names>B.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Choudhary</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Regan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Persistence and Evolution of SARS&#x02010;CoV&#x02010;2 in an Immunocompromised Host</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>383</volume>, no. <issue>23</issue> (<year>2020</year>): <fpage>2291</fpage>&#x02013;<lpage>2293</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMc2031364</pub-id>.<pub-id pub-id-type="pmid">33176080</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="irv70121-cit-0006">
<string-name>
<given-names>V.</given-names>
<surname>Borges</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Isidro</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Cunha</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Term Evolution of SARS&#x02010;CoV&#x02010;2 in an Immunocompromised Patient With Non&#x02010;Hodgkin Lymphoma</article-title>,&#x0201d; <source>mSphere</source>
<volume>6</volume>, no. <issue>4</issue> (<year>2021</year>): <elocation-id>e0024421</elocation-id>, <pub-id pub-id-type="doi">10.1128/mSphere.00244-21</pub-id>.<pub-id pub-id-type="pmid">34319130</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="irv70121-cit-0007">
<string-name>
<given-names>S. A.</given-names>
<surname>Kemp</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Collier</surname>
</string-name>, <string-name>
<given-names>R. P.</given-names>
<surname>Datir</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>SARS&#x02010;CoV&#x02010;2 Evolution During Treatment of Chronic Infection</article-title>,&#x0201d; <source>Nature</source>
<volume>592</volume>, no. <issue>7853</issue> (<year>2021</year>): <fpage>277</fpage>&#x02013;<lpage>282</lpage>, <pub-id pub-id-type="doi">10.1038/s41586-021-03291-y</pub-id>.<pub-id pub-id-type="pmid">33545711</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="irv70121-cit-0008">
<string-name>
<given-names>S.</given-names>
<surname>Weigang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Fuchs</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Zimmer</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Within&#x02010;Host Evolution of SARS&#x02010;CoV&#x02010;2 in an Immunosuppressed COVID&#x02010;19 Patient as a Source of Immune Escape Variants</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>12</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>6405</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-021-26602-3</pub-id>.</mixed-citation></ref><ref id="irv70121-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="irv70121-cit-0009">
<string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Choudhary</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Regan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>SARS&#x02010;CoV&#x02010;2 Viral Clearance and Evolution Varies by Type and Severity of Immunodeficiency</article-title>,&#x0201d; <source>Science Translational Medicine</source>
<volume>16</volume>, no. <issue>731</issue> (<year>2024</year>): <elocation-id>eadk1599</elocation-id>, <pub-id pub-id-type="doi">10.1126/scitranslmed.adk1599</pub-id>.<pub-id pub-id-type="pmid">38266109</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="irv70121-cit-0010">
<collab collab-type="authors">Centers for Disease Control and Prevention</collab>
. <article-title>Interim Clinical Considerations for Use of COVID&#x02010;19 Vaccines in the United States</article-title>, <ext-link xlink:href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02" ext-link-type="uri">https://www.cdc.gov/vaccines/covid&#x02010;19/clinical&#x02010;considerations/interim&#x02010;considerations&#x02010;us.html#table&#x02010;02</ext-link>.</mixed-citation></ref><ref id="irv70121-bib-0011"><label>11</label><mixed-citation publication-type="book" id="irv70121-cit-0011">
<string-name>
<given-names>S.</given-names>
<surname>Moola</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Munn</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Tufanaru</surname>
</string-name>, et&#x000a0;al., &#x0201c;<part-title>Systematic Reviews of Etiology and Risk</part-title>,&#x0201d; in <source>JBI Manual for Evidence Synthesis</source>, eds. <person-group person-group-type="editor">
<string-name>
<given-names>E. L. C.</given-names>
<surname>Aromataris</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>K.</given-names>
<surname>Porritt</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>B.</given-names>
<surname>Pilla</surname>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<given-names>Z.</given-names>
<surname>Jordan</surname>
</string-name>
</person-group> (<publisher-name>JBI</publisher-name>, <year>2020</year>) 2024:chap 7.</mixed-citation></ref><ref id="irv70121-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="irv70121-cit-0012">
<string-name>
<given-names>Z.</given-names>
<surname>Munn</surname>
</string-name>, <string-name>
<given-names>T. H.</given-names>
<surname>Barker</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Moola</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methodological Quality of Case Series Studies: An Introduction to the JBI Critical Appraisal Tool</article-title>,&#x0201d; <source>JBI Evidence Synthesis</source>
<volume>18</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>2127</fpage>&#x02013;<lpage>2133</lpage>, <pub-id pub-id-type="doi">10.11124/jbisrir-d-19-00099</pub-id>.<pub-id pub-id-type="pmid">33038125</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="irv70121-cit-0013">
<string-name>
<given-names>T. H.</given-names>
<surname>Barker</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Hasanoff</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Aromataris</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Revised JBI Critical Appraisal Tool for the Assessment of Risk of Bias for Cohort Studies</article-title>,&#x0201d; <source>JBI Evidence Synthesis</source>
<volume>23</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>441</fpage>&#x02013;<lpage>453</lpage>, <pub-id pub-id-type="doi">10.11124/jbies-24-00103</pub-id>.<pub-id pub-id-type="pmid">39177422</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="irv70121-cit-0014">
<string-name>
<given-names>P.</given-names>
<surname>Vizcarra</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>P&#x000e9;rez&#x02010;El&#x000ed;as</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Quereda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Description of COVID&#x02010;19 in HIV&#x02010;Infected Individuals: A Single&#x02010;Centre, Prospective Cohort</article-title>,&#x0201d; <source>Lancet HIV</source>
<volume>7</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>e554</fpage>&#x02013;<lpage>e564</lpage>, <pub-id pub-id-type="doi">10.1016/s2352-3018(20)30164-8</pub-id>.<pub-id pub-id-type="pmid">32473657</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="irv70121-cit-0015">
<article-title>PRISMA</article-title>, <ext-link xlink:href="http://www.prisma-statement.org/" ext-link-type="uri">http://www.prisma&#x02010;statement.org/</ext-link>.</mixed-citation></ref><ref id="irv70121-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="irv70121-cit-0016">
<string-name>
<given-names>B.</given-names>
<surname>Bailly</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>P&#x000e9;r&#x000e9;</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Veyer</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Persistent Coronavirus Disease 2019 (COVID&#x02010;19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS&#x02010;CoV&#x02010;2)&#x02010;Specific Monoclonal Antibodies</article-title>,&#x0201d; <source>Clinical Infectious Diseases</source>
<volume>74</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>1706</fpage>&#x02013;<lpage>1707</lpage>, <pub-id pub-id-type="doi">10.1093/cid/ciab868</pub-id>.<pub-id pub-id-type="pmid">34598278</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="irv70121-cit-0017">
<string-name>
<given-names>M. D. P.</given-names>
<surname>Cunha</surname>
</string-name>, <string-name>
<given-names>A. P. P.</given-names>
<surname>Vilela</surname>
</string-name>, <string-name>
<given-names>C. V.</given-names>
<surname>Molina</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Atypical Prolonged Viral Shedding With Intra&#x02010;Host SARS&#x02010;CoV&#x02010;2 Evolution in a Mildly Affected Symptomatic Patient</article-title>,&#x0201d; <source>Frontiers in Medicine</source>
<volume>8</volume> (<year>2021</year>): <elocation-id>760170</elocation-id>, <pub-id pub-id-type="doi">10.3389/fmed.2021.760170</pub-id>.<pub-id pub-id-type="pmid">34901074</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="irv70121-cit-0018">
<string-name>
<given-names>L.</given-names>
<surname>P&#x000e9;rez&#x02010;Lago</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ald&#x000e1;miz&#x02010;Echevarr&#x000ed;a</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Garc&#x000ed;a&#x02010;Mart&#x000ed;nez</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Different Within&#x02010;Host Viral Evolution Dynamics in Severely Immunosuppressed Cases With Persistent SARS&#x02010;CoV&#x02010;2</article-title>,&#x0201d; <source>Biomedicine</source>
<volume>9</volume>, no. <issue>7</issue> (<year>2021</year>): <elocation-id>808</elocation-id>, <pub-id pub-id-type="doi">10.3390/biomedicines9070808</pub-id>.</mixed-citation></ref><ref id="irv70121-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="irv70121-cit-0019">
<string-name>
<given-names>S. W.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Virological Characteristics and the Rapid Antigen Test as Deisolation Criteria in Immunocompromised Patients With COVID&#x02010;19: A Prospective Cohort Study</article-title>,&#x0201d; <source>Journal of Medical Virology</source>
<volume>95</volume>, no. <issue>11</issue> (<year>2023</year>): <elocation-id>e29228</elocation-id>, <pub-id pub-id-type="doi">10.1002/jmv.29228</pub-id>.<pub-id pub-id-type="pmid">38009999</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="irv70121-cit-0020">
<string-name>
<given-names>Z.</given-names>
<surname>Raglow</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Surie</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Chappell</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>SARS&#x02010;CoV&#x02010;2 Shedding and Evolution in Patients Who Were Immunocompromised During the Omicron Period: A Multicentre, Prospective Analysis</article-title>,&#x0201d; <source>Lancet Microbe</source>
<volume>5</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>e235</fpage>&#x02013;<lpage>e246</lpage>, <pub-id pub-id-type="doi">10.1016/s2666-5247(23)00336-1</pub-id>.<pub-id pub-id-type="pmid">38286131</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="irv70121-cit-0021">
<string-name>
<given-names>S. W.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Characteristics and Risk Factors of Prolonged Viable Virus Shedding in Immunocompromised Patients With COVID&#x02010;19: A Prospective Cohort Study</article-title>,&#x0201d; <source>Journal of Infection</source>
<volume>86</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>412</fpage>&#x02013;<lpage>414</lpage>, <pub-id pub-id-type="doi">10.1016/j.jinf.2023.01.024</pub-id>.<pub-id pub-id-type="pmid">36682630</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="irv70121-cit-0022">
<string-name>
<given-names>S. Y.</given-names>
<surname>Lim</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Association Between Antibody Responses and Prolonged Viable SARS&#x02010;CoV&#x02010;2 Shedding in Immunocompromised Patients: A Prospective Cohort Study</article-title>,&#x0201d; <source>Journal of Infectious Diseases</source>
<volume>229</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>1722</fpage>&#x02013;<lpage>1727</lpage>, <pub-id pub-id-type="doi">10.1093/infdis/jiad579</pub-id>.</mixed-citation></ref><ref id="irv70121-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="irv70121-cit-0023">
<string-name>
<given-names>M.</given-names>
<surname>Spinicci</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mazzoni</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Coppi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Term SARS&#x02010;CoV&#x02010;2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications</article-title>,&#x0201d; <source>Journal of Clinical Immunology</source>
<volume>42</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>1371</fpage>&#x02013;<lpage>1378</lpage>, <pub-id pub-id-type="doi">10.1007/s10875-022-01313-6</pub-id>.<pub-id pub-id-type="pmid">35779200</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="irv70121-cit-0024">
<string-name>
<given-names>P. A.</given-names>
<surname>Reuken</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Stallmach</surname>
</string-name>, <string-name>
<given-names>M. W.</given-names>
<surname>Pletz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Severe Clinical Relapse in an Immunocompromised Host With Persistent SARS&#x02010;CoV&#x02010;2 Infection</article-title>,&#x0201d; <source>Leukemia</source>
<volume>35</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>920</fpage>&#x02013;<lpage>923</lpage>, <pub-id pub-id-type="doi">10.1038/s41375-021-01175-8</pub-id>.<pub-id pub-id-type="pmid">33608636</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="irv70121-cit-0025">
<string-name>
<given-names>M.</given-names>
<surname>Iwasaki</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hashimoto</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Takeuchi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Relapse of COVID&#x02010;19 and Viral Evolution in a Patient With Good Syndrome: A Case Report</article-title>,&#x0201d; <source>Cureus</source>
<volume>16</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>e52592</elocation-id>, <pub-id pub-id-type="doi">10.7759/cureus.52592</pub-id>.<pub-id pub-id-type="pmid">38371040</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="irv70121-cit-0026">
<string-name>
<given-names>J.</given-names>
<surname>Bullard</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Dust</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Funk</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples</article-title>,&#x0201d; <source>Clinical Infectious Diseases</source>
<volume>71</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>2663</fpage>&#x02013;<lpage>2666</lpage>, <pub-id pub-id-type="doi">10.1093/cid/ciaa638</pub-id>.<pub-id pub-id-type="pmid">32442256</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="irv70121-cit-0027">
<string-name>
<given-names>T.</given-names>
<surname>Murata</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sakurai</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Suzuki</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Shedding of Viable Virus in Asymptomatic SARS&#x02010;CoV&#x02010;2 Carriers</article-title>,&#x0201d; <source>mSphere</source>
<volume>6</volume>, no. <issue>3</issue> (<year>2021</year>): <elocation-id>e0001921</elocation-id>, <pub-id pub-id-type="doi">10.1128/mSphere.00019-21</pub-id>.</mixed-citation></ref><ref id="irv70121-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="irv70121-cit-0028">
<string-name>
<given-names>A.</given-names>
<surname>Singanayagam</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Patel</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Charlett</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Duration of Infectiousness and Correlation With RT&#x02010;PCR Cycle Threshold Values in Cases of COVID&#x02010;19, England, January to May 2020</article-title>,&#x0201d; <source>Euro Surveillance</source>
<volume>25</volume>, no. <issue>32</issue> (<year>2020</year>): <elocation-id>2001483</elocation-id>, <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.32.2001483</pub-id>.<pub-id pub-id-type="pmid">32794447</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="irv70121-cit-0029">
<string-name>
<given-names>M. M.</given-names>
<surname>Arons</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Hatfield</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Reddy</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Presymptomatic SARS&#x02010;CoV&#x02010;2 Infections and Transmission in a Skilled Nursing Facility</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>382</volume>, no. <issue>22</issue> (<year>2020</year>): <fpage>2081</fpage>&#x02013;<lpage>2090</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2008457</pub-id>.<pub-id pub-id-type="pmid">32329971</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="irv70121-cit-0030">
<string-name>
<given-names>K.</given-names>
<surname>Basile</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>McPhie</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Carter</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cell&#x02010;Based Culture Informs Infectivity and Safe De&#x02010;Isolation Assessments in Patients With Coronavirus Disease 2019</article-title>,&#x0201d; <source>Clinical Infectious Diseases</source>
<volume>73</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>e2952</fpage>&#x02013;<lpage>e2959</lpage>, <pub-id pub-id-type="doi">10.1093/cid/ciaa1579</pub-id>.<pub-id pub-id-type="pmid">33098412</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="irv70121-cit-0031">
<string-name>
<given-names>V.</given-names>
<surname>Nussenblatt</surname>
</string-name>, <string-name>
<given-names>A. E.</given-names>
<surname>Roder</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Das</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Yearlong COVID&#x02010;19 Infection Reveals Within&#x02010;Host Evolution of SARS&#x02010;CoV&#x02010;2 in a Patient With B&#x02010;Cell Depletion</article-title>,&#x0201d; <source>Journal of Infectious Diseases</source>
<volume>225</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>1118</fpage>&#x02013;<lpage>1123</lpage>, <pub-id pub-id-type="doi">10.1093/infdis/jiab622</pub-id>.<pub-id pub-id-type="pmid">34940844</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="irv70121-cit-0032">
<string-name>
<given-names>M.</given-names>
<surname>Santos Bravo</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Berengua</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Mar&#x000ed;n</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Viral Culture Confirmed SARS&#x02010;CoV&#x02010;2 Subgenomic RNA Value as a Good Surrogate Marker of Infectivity</article-title>,&#x0201d; <source>Journal of Clinical Microbiology</source>
<volume>60</volume>, no. <issue>1</issue> (<year>2022</year>): <elocation-id>e0160921</elocation-id>, <pub-id pub-id-type="doi">10.1128/jcm.01609-21</pub-id>.<pub-id pub-id-type="pmid">34669457</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="irv70121-cit-0033">
<string-name>
<given-names>A.</given-names>
<surname>Phuphuakrat</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Pasomsub</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Srichatrapimuk</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Detectable Duration of Viable SARS&#x02010;CoV&#x02010;2, Total and Subgenomic SARS&#x02010;CoV&#x02010;2 RNA in Noncritically Ill COVID&#x02010;19 Patients: A Prospective Cohort Study</article-title>,&#x0201d; <source>Microbiology Spectrum</source>
<volume>10</volume>, no. <issue>3</issue> (<year>2022</year>): <elocation-id>e0050322</elocation-id>, <pub-id pub-id-type="doi">10.1128/spectrum.00503-22</pub-id>.<pub-id pub-id-type="pmid">35604133</pub-id>
</mixed-citation></ref><ref id="irv70121-bib-0034"><label>34</label><mixed-citation publication-type="miscellaneous" id="irv70121-cit-0034">
<collab collab-type="authors">Centers for Disease Control and Prevention</collab>
. <article-title>Infection Control Guidance: SARS&#x02010;CoV&#x02010;2</article-title>, <ext-link xlink:href="https://www.cdc.gov/covid/hcp/infection-control/index.html" ext-link-type="uri">https://www.cdc.gov/covid/hcp/infection&#x02010;control/index.html</ext-link>.</mixed-citation></ref></ref-list></back></article>